Antihyperglykämische Therapie bei Diabetes mellitus Typ 2 (Update 2023)

Martin Clodi; Heidemarie Abrahamian; Helmut Brath; Guntram Schernthaner; Johann Brix; Bernhard Ludvik; Heinz Drexel; Christoph H. Saely; Peter Fasching; Gersina Rega-Kaun; Bernhard Föger; Claudia Francesconi; Elke Fröhlich-Reiterer; Alexandra Kautzky-Willer; Jürgen Harreiter; Anton Luger; Michael Resl; Michaela Riedl; Yvonne Winhofer; Sabine E. Hofer; Friedrich Hoppichler; Joakim Huber; Susanne Kaser; Claudia Ress; Monika Lechleitner; Felix Aberer; Julia K. Mader; Harald Sourij; Hermann Toplak; Bernhard Paulweber; Lars Stechemesser; Thomas Pieber; Rudolf Prager; Harald Stingl; Thomas Stulnig; Birgit Rami-Merhar; Heinz Drexel; Michael Roden; Christian Schelkshorn; Thomas C. Wascher; Raimund Weitgasser; Sandra Zlamal-Fortunat

doi:10.1007/s00508-023-02186-4

Antihyperglykämische Therapie bei Diabetes mellitus Typ 2 (Update 2023)

Martin Clodi^*
, Heidemarie Abrahamian
, Helmut Brath
, Guntram Schernthaner
, Johann Brix
, Bernhard Ludvik
, Heinz Drexel
, Christoph H. Saely
, Peter Fasching
, Gersina Rega-Kaun
, Bernhard Föger
, Claudia Francesconi
, Elke Fröhlich-Reiterer
, Alexandra Kautzky-Willer
, Jürgen Harreiter
, Anton Luger
, Michael Resl
, Michaela Riedl
, Yvonne Winhofer
, Sabine E. Hofer

Friedrich Hoppichler, Joakim Huber, Susanne Kaser, Claudia Ress, Monika Lechleitner, Felix Aberer, Julia K. Mader, Harald Sourij, Hermann Toplak, Bernhard Paulweber, Lars Stechemesser, Thomas Pieber, Rudolf Prager, Harald Stingl, Thomas Stulnig, Birgit Rami-Merhar, Heinz Drexel, Michael Roden, Christian Schelkshorn, Thomas C. Wascher, Raimund Weitgasser, Sandra Zlamal-Fortunat

^*Korrespondierende:r Autor:in für diese Arbeit

externe Lehrende

Publikation: Beitrag in Fachzeitschrift (peer-reviewed) › Artikel in Fachzeitschrift

4 Zitate (Scopus)

Abstract

Hyperglycemia significantly contributes to complications in patients with diabetes mellitus. While lifestyle interventions remain cornerstones of disease prevention and treatment, most patients with type 2 diabetes will eventually require pharmacotherapy for glycemic control. The definition of individual targets regarding optimal therapeutic efficacy and safety as well as cardiovascular effects is of great importance. In this guideline we present the most current evidence-based best clinical practice data for healthcare professionals.

Titel in Übersetzung	Antihyperglycemic treatment guidelines for diabetes mellitus type 2 (Update 2023)
Originalsprache	Deutsch
Seiten (von - bis)	32-44
Seitenumfang	13
Fachzeitschrift	Wiener Klinische Wochenschrift
Jahrgang	135
DOIs	https://doi.org/10.1007/s00508-023-02186-4
Publikationsstatus	Veröffentlicht - Jan. 2023

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gute Gesundheit und Wohlergehen

Schlagwörter

Diabetes mellitus Type 2
Therapy Glucose lowering

ASJC Scopus Sachgebiete

Allgemeine Medizin

Zugriff auf Dokument

10.1007/s00508-023-02186-4

Andere Dateien und Links

Verknüpfung zur Publikation in Scopus

Dieses zitieren

Clodi, M., Abrahamian, H., Brath, H., Schernthaner, G., Brix, J., Ludvik, B., Drexel, H., Saely, C. H., Fasching, P., Rega-Kaun, G., Föger, B., Francesconi, C., Fröhlich-Reiterer, E., Kautzky-Willer, A., Harreiter, J., Luger, A., Resl, M., Riedl, M., Winhofer, Y., ... Zlamal-Fortunat, S. (2023). Antihyperglykämische Therapie bei Diabetes mellitus Typ 2 (Update 2023). Wiener Klinische Wochenschrift, 135, 32-44. https://doi.org/10.1007/s00508-023-02186-4

@article{b4f04b7d14e04645b9cbf2e62553b8b4,

title = "Antihyperglyk{\"a}mische Therapie bei Diabetes mellitus Typ 2 (Update 2023)",

abstract = "Hyperglycemia significantly contributes to complications in patients with diabetes mellitus. While lifestyle interventions remain cornerstones of disease prevention and treatment, most patients with type 2 diabetes will eventually require pharmacotherapy for glycemic control. The definition of individual targets regarding optimal therapeutic efficacy and safety as well as cardiovascular effects is of great importance. In this guideline we present the most current evidence-based best clinical practice data for healthcare professionals.",

keywords = "Diabetes mellitus Type 2, Therapy Glucose lowering",

author = "Martin Clodi and Heidemarie Abrahamian and Helmut Brath and Guntram Schernthaner and Johann Brix and Bernhard Ludvik and Heinz Drexel and Saely, \{Christoph H.\} and Peter Fasching and Gersina Rega-Kaun and Bernhard F{\"o}ger and Claudia Francesconi and Elke Fr{\"o}hlich-Reiterer and Alexandra Kautzky-Willer and J{\"u}rgen Harreiter and Anton Luger and Michael Resl and Michaela Riedl and Yvonne Winhofer and Hofer, \{Sabine E.\} and Friedrich Hoppichler and Joakim Huber and Susanne Kaser and Claudia Ress and Monika Lechleitner and Felix Aberer and Mader, \{Julia K.\} and Harald Sourij and Hermann Toplak and Bernhard Paulweber and Lars Stechemesser and Thomas Pieber and Rudolf Prager and Harald Stingl and Thomas Stulnig and Birgit Rami-Merhar and Heinz Drexel and Michael Roden and Christian Schelkshorn and Wascher, \{Thomas C.\} and Raimund Weitgasser and Sandra Zlamal-Fortunat",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = jan,

doi = "10.1007/s00508-023-02186-4",

language = "Deutsch",

volume = "135",

pages = "32--44",

journal = "Wiener Klinische Wochenschrift",

issn = "0043-5325",

publisher = "Springer",

}

Clodi, M, Abrahamian, H, Brath, H, Schernthaner, G, Brix, J, Ludvik, B, Drexel, H, Saely, CH, Fasching, P, Rega-Kaun, G, Föger, B, Francesconi, C, Fröhlich-Reiterer, E, Kautzky-Willer, A, Harreiter, J, Luger, A, Resl, M, Riedl, M, Winhofer, Y, Hofer, SE, Hoppichler, F, Huber, J, Kaser, S, Ress, C, Lechleitner, M, Aberer, F, Mader, JK, Sourij, H, Toplak, H, Paulweber, B, Stechemesser, L, Pieber, T, Prager, R, Stingl, H, Stulnig, T, Rami-Merhar, B, Drexel, H, Roden, M, Schelkshorn, C, Wascher, TC, Weitgasser, R & Zlamal-Fortunat, S 2023, 'Antihyperglykämische Therapie bei Diabetes mellitus Typ 2 (Update 2023)', Wiener Klinische Wochenschrift, Jg. 135, S. 32-44. https://doi.org/10.1007/s00508-023-02186-4

TY - JOUR

T1 - Antihyperglykämische Therapie bei Diabetes mellitus Typ 2 (Update 2023)

AU - Clodi, Martin

AU - Abrahamian, Heidemarie

AU - Brath, Helmut

AU - Schernthaner, Guntram

AU - Brix, Johann

AU - Ludvik, Bernhard

AU - Drexel, Heinz

AU - Saely, Christoph H.

AU - Fasching, Peter

AU - Rega-Kaun, Gersina

AU - Föger, Bernhard

AU - Francesconi, Claudia

AU - Fröhlich-Reiterer, Elke

AU - Kautzky-Willer, Alexandra

AU - Harreiter, Jürgen

AU - Luger, Anton

AU - Resl, Michael

AU - Riedl, Michaela

AU - Winhofer, Yvonne

AU - Hofer, Sabine E.

AU - Hoppichler, Friedrich

AU - Huber, Joakim

AU - Kaser, Susanne

AU - Ress, Claudia

AU - Lechleitner, Monika

AU - Aberer, Felix

AU - Mader, Julia K.

AU - Sourij, Harald

AU - Toplak, Hermann

AU - Paulweber, Bernhard

AU - Stechemesser, Lars

AU - Pieber, Thomas

AU - Prager, Rudolf

AU - Stingl, Harald

AU - Stulnig, Thomas

AU - Rami-Merhar, Birgit

AU - Drexel, Heinz

AU - Roden, Michael

AU - Schelkshorn, Christian

AU - Wascher, Thomas C.

AU - Weitgasser, Raimund

AU - Zlamal-Fortunat, Sandra

PY - 2023/1

Y1 - 2023/1

N2 - Hyperglycemia significantly contributes to complications in patients with diabetes mellitus. While lifestyle interventions remain cornerstones of disease prevention and treatment, most patients with type 2 diabetes will eventually require pharmacotherapy for glycemic control. The definition of individual targets regarding optimal therapeutic efficacy and safety as well as cardiovascular effects is of great importance. In this guideline we present the most current evidence-based best clinical practice data for healthcare professionals.

AB - Hyperglycemia significantly contributes to complications in patients with diabetes mellitus. While lifestyle interventions remain cornerstones of disease prevention and treatment, most patients with type 2 diabetes will eventually require pharmacotherapy for glycemic control. The definition of individual targets regarding optimal therapeutic efficacy and safety as well as cardiovascular effects is of great importance. In this guideline we present the most current evidence-based best clinical practice data for healthcare professionals.

KW - Diabetes mellitus Type 2

KW - Therapy Glucose lowering

UR - https://www.scopus.com/pages/publications/85153918990

U2 - 10.1007/s00508-023-02186-4

DO - 10.1007/s00508-023-02186-4

M3 - Artikel in Fachzeitschrift

C2 - 37101023

AN - SCOPUS:85153918990

SN - 0043-5325

VL - 135

SP - 32

EP - 44

JO - Wiener Klinische Wochenschrift

JF - Wiener Klinische Wochenschrift

ER -